EGFR and esophageal squamous cell carcinoma: Here in this study, we utilized ESCC PDXs and cell lines to systematically identify the most promising EGFR blocker and provide a more accurate evidence for clinical trials, followed by its further investigations of underlying mechanisms, predictive biomarkers, and acquired resistant mechanisms together with reversing strategies.